US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews
Executive Summary
FDA's Peter Stein calls idea "useful"; rare disease experts would temporarily serve on standing advisory committees when needed.
You may also be interested in...
Rare Disease Challenges At US FDA: CDER Director Says More Staff, Not Reorganization, Will Fix Issues
Rather than changing the agency's structure to create more focus on rare diseases, Patrizia Cavazzoni wants funding for people to do the necessary work.
Accelerated Approval Reform Proposals Worry Industry: ‘Science Doesn’t Move The Same Way’
During House hearing, PhRMA and BIO highlight provisions of PDUFA VII agreement that the associations say would benefit the pathway more than the additional reforms being considered by Congress.
US FDA Plans Rare Disease Center Of Excellence, But Not "That" Kind Of COE
A COE modeled after the Oncology Center of Excellence, which stakeholders had proposed, is not in the works, but rather a more virtual structure.